Dynamics of Low-Level Viremia and Immune Activation after Switching to a Darunavir-Based Regimen
Authors:
- Arjen J. StamASArjen J. Stam
- Ninée V. E. J. BuchholtzNBNinée V. E. J. Buchholtz
- Wouter F. W. BiermanWBWouter F. W. Bierman
- Reinout van CrevelRCReinout van Crevel
- Andy I. M. HoepelmanAHAndy I. M. Hoepelman
- Mark A. A. ClaassenMCMark A. A. Claassen
- Heidi S. M. AmmerlaanHAHeidi S. M. Ammerlaan
- Berend J. van WelzenBWBerend J. van Welzen
- Marjo E. E. van KasterenMKMarjo E. E. van Kasteren
- Steven F. L. van LelyveldSLSteven F. L. van Lelyveld
- Dorien de JongDJDorien de Jong
- Kiki TesselaarKTKiki Tesselaar
Open Access
Abstract
There is an ongoing debate regarding whether low-level viremia (LLV), in particular persistent LLV, during HIV treatment with optimal adherence originates from low-level viral replication, viral production, or both. We performed an observational study in 30 individuals with LLV who switched to a boosted darunavir (DRV)-based therapy. In-depth virological analyses were used to characterize the viral population and the (activity) of the viral reservoir. Immune activation was examined using cell-bound and soluble markers. The primary outcome was defined as the effect on HIV-RNA and was categorized by responders (50 cp/mL). At week 24, 53% of the individuals were considered responders, 40% non-responders, and 7% could not be assigned. Sequencing showed no evolution or selection of drug resistance in the non-responders. Production of defective virus with mutations in either the protease (D25N) or RT active site contributed to persistent LLV in two individuals. We show that in about half of the study participants, the switch to a DRV-based regimen resulted in a viral response indicative of ongoing low-level viral replication as the cause of LLV before the switch. Our data confirm that in clinical management, high genetic barrier drugs like DRV are a safe choice, irrespective of the source of LLV.Keywords
Funding Information
- An investigator-initiated research (TMC114IFD4024)
This publication has 44 references indexed in Scilit:
- Magnitude of Virologic Blips Is Associated With a Higher Risk for Virologic Rebound in HIV-Infected Individuals: A Recurrent Events AnalysisThe Journal of Infectious Diseases, 2012
- Antiretroviral Drug Resistance in HIV-1–Infected Patients Experiencing Persistent Low-Level Viremia During First-Line TherapyThe Journal of Infectious Diseases, 2011
- A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell ResponseThe Journal of Infectious Diseases, 2011
- Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapyProceedings of the National Academy of Sciences, 2009
- The Use of Darunavir/Ritonavir as Intensification in Low Viremic HIV-Infected Patients Treated with Boosted Protease Inhibitor-Containing RegimensJournal of the International Association of Physicians in AIDS Care, 2009
- Effect of the Active Site D25N Mutation on the Structure, Stability, and Ligand Binding of the Mature HIV-1 ProteaseJournal of Biological Chemistry, 2008
- Relationship between T Cell Activation and CD4+T Cell Count in HIV‐Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of TherapyThe Journal of Infectious Diseases, 2008
- Decreased Adherence to Antiretroviral Therapy Observed prior to Transient Human Immunodeficiency Virus Type 1 ViremiaThe Journal of Infectious Diseases, 2007
- Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional studyAnnals of the Rheumatic Diseases, 2007
- T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral TherapyThe Journal of Infectious Diseases, 2003